Fortress Biotech forms new subsidiary, Aevitas Therapeutics

Subsidiary to develop novel AAV gene therapy treatments for complement-mediated.

Irregularities in these proteins can play a vital role in an array of complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Recent research has suggested that complement regulatory proteins could also play a key role in the pathogenesis of age-related macular degeneration.

Dr Lindsay A. Rosenwald, Fortress Biotech’s Chairman, President and Chief Executive Officer, said: “We are thrilled to work on this potentially groundbreaking technology in numerous areas of unmet need as we continue to establish our capabilities in the gene therapy space.”